Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.89 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.89 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.89 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.89 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.89 |
| ▸ | SRC | P12931 | 2/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.89 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.89 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.89 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.89 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.89 |
| ▸ | LDHA | P00338 | 1/20 | 0.89 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.89 |
| ▸ | FBP1 | P09467 | 1/20 | 0.89 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.89 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.89 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.89 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL20304185 | 0.94 | P2RY1 (0.89) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL790420 | 0.94 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL20277555 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL8572634 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL13170051 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL19420134 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL132458 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL144997 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL1338615 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL11977309 | 0.94 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723068-B2 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | PHARMAMAR, S.A. (ES) | 2010-05-25 | — | — | US | disclosed |
| EP-1576159-B9 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-12-16 | — | — | EP | disclosed |
| EP-1576159-B1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-07-01 | — | — | EP | disclosed |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | PHARMA MAR, S.A. (ES) | 2008-07-31 | — | — | US | disclosed |
| US-20060134764-A1 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | VELASCO IGLESIAS ANA | 2006-06-22 | — | — | US | disclosed |
| CN-1753996-A | The gene cluster involved in safracin biosynthesis and its uses for genetic engineering | PHARMA MAR SA (ES) | 2006-03-29 | — | — | CN | disclosed |
| EP-1576159-A1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056998-A1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR, S.A. (ES) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134764-A1 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | COASY, MYCBP, MYC | ADORA1 4875/4885PDE4D 4165/4885PDE3A 4741/4885 |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | COASY, MYCBP, MYC | ADORA1 4871/4885PDE4D 4150/4885PDE3A 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.